@article{c98efdb0dc534748965f8c22814eceb2,
title = "Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample",
abstract = "Antipsychotic-induced weight gain (AIWG) is a common side effect with a high genetic contribution. We reanalyzed genome-wide association study (GWAS) data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) selecting a refined subset of patients most suitable for AIWG studies. The final GWAS was conducted in N=189 individuals. The top polymorphisms were analyzed in a second cohort of N=86 patients. None of the single-nucleotide polymorphisms was significant at the genome-wide threshold of 5x10 -8. We observed interesting trends for rs9346455 (P=6.49x10 -6) upstream of OGFRL1, the intergenic variants rs7336345 (P=1.31 × 10 -5) and rs1012650 (P=1.47 × 10 -5), and rs1059778 (P=1.49x10 -5) in IBA57. In the second cohort, rs9346455 showed significant association with AIWG (P=0.005). The combined meta-analysis P-value for rs9346455 was 1.09 × 10 -7. Our reanalysis of the CATIE GWAS data revealed interesting new variants associated with AIWG. As the functional relevance of these polymorphisms is yet to be determined, further studies are needed.",
author = "Brandl, {E. J.} and Tiwari, {A. K.} and Zai, {C. C.} and Nurmi, {E. L.} and Chowdhury, {N. I.} and T. Arenovich and M. Sanches and Goncalves, {V. F.} and Shen, {J. J.} and Lieberman, {J. A.} and Meltzer, {H. Y.} and Kennedy, {J. L.} and M{\"u}ller, {D. J.}",
note = "Funding Information: The principal investigators of the CATIE trial were Jeffrey A Lieberman, MD, T Scott Stroup, MD, MPH, and Joseph P McEvoy, MD. The CATIE trial was funded by a grant from the National Institute of Mental Health (N01 MH900001) along with MH074027 (PI PF Sullivan). Genotyping was funded by Eli Lilly and Company. AKT: recipient of NARSAD 2010 young investigator award. CCZ: recipient of NARSAD Young Investigator Award; postdoctoral fellowship from the American Foundation for Suicide Prevention (2PDF-00065-1208-0609-1209); and Eli Lilly Canada. ELN: supported by the NIMH Career Development Award K23 MH094613-01. NIC: OMHF Research Studentship. DJM: CIHR operating grant (Genetics of antipsychotics induced metabolic syndrome, MOP 89853 and Development, validation, and benefits of a genetic risk model for AIWG; MOP 142192); NARSAD Independent Investigator Award, Early Researcher Award by the Ministry of Research and Innovation of Ontario, CIHR Michael Smith New Investigator Salary Prize for Research in Schizophrenia and OMHF New Investigator Fellowship. JLK: recipient of a CIHR operating grant (Strategies for gene discovery in schizophrenia: subphenotypes, deep sequencing and interactions, MOP 115097), recipient of a Genome Canada grant. The funding sources did not have any influence on study design, data analysis and writing of the manuscript. Publisher Copyright: {\textcopyright} 2016 Macmillan Publishers Limited.",
year = "2016",
month = aug,
day = "1",
doi = "10.1038/tpj.2015.59",
language = "English (US)",
volume = "16",
pages = "352--356",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",
}